Revolutionizing regeneration: stem cells transform treatment of hidrotic ectodermal dysplasia (Clouston syndrome)

Clouston syndrome is a rare autosomal dominant form of hidrotic ectodermal dysplasia that presents significant challenges due to its multisystemic manifestations and limited therapeutic options. This review explores the functional role of stem cells in the treatment and management of Clouston syndrome, highlighting advancements in regenerative medicine and stem cell therapy. Stem cell types such as mesenchymal stem cells (MSCs), epidermal stem cells (EpSCs), and induced pluripotent stem cells (iPSCs) have shown promise in regenerating ectodermal derivatives like skin, hair, and nails. Gene-editing technologies, including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas9), can correct pathogenic mutations in the GJB6 gene. Emerging techniques in tissue engineering and three dimensional (3D) bioprinting are also discussed, focusing on their potential to create patient-specific, bioengineered constructs. Clinical trials in related genetic disorders provide evidence for the feasibility of these approaches in improving patient outcomes. However, challenges such as immune rejection, ethical concerns, and stem cell production scalability remain barriers. Addressing these issues requires interdisciplinary collaboration, sustained funding, and targeted research. This review underscores the transformative potential of regenerative medicine. It highlights the need for continued efforts to develop curative strategies for treatment, integrating stem cell-based therapies, gene editing, and bioengineering.